Four Weeks on Semaglutide and No Weight Loss Yet

Is it normal to see no results after four weeks on semaglutide?

Yes, and a question our prescribers hear most weeks is some version of: "I've been on it a month and nothing's happened, is it working?" The honest answer is that four weeks is almost always too early to judge. The licensed Wegovy titration schedule starts at 0.25mg weekly, moving to 0.5mg at around week five, then 1mg, 1.7mg and finally 2.4mg, the standard maintenance dose. That initial 0.25mg step exists because semaglutide causes nausea and GI discomfort in many people; starting low gives your body time to adjust. It is not a therapeutic weight-loss dose by design.

Clinical trials bear this out. The STEP 1 study, published in the New England Journal of Medicine, showed an average weight reduction of around 15% over 68 weeks at 2.4mg, a figure that reflects what happens across the whole titration arc, not the first month. Most participants were still climbing through the dose schedule when their four-week mark passed. You can read more about how the medicine works across that timeline on our semaglutide weight loss overview.

If you started on Wegovy recently and feel like nothing is happening, that feeling is valid. It's also, in most cases, completely consistent with normal treatment progression. Give it time to reach the dose that's actually meant to do the work.

Could something specific be slowing things down?

There are a handful of things worth considering if the scales are completely flat. First, fluid. The early weeks of any significant diet or metabolic change often come with water retention, your body's glycogen stores shift, hormones fluctuate, and some people hold a few extra pounds of fluid right as they'd expect to see the first drop. This doesn't show on a bathroom scale as fat loss, even when it's happening. Body measurements, how your clothes fit, and energy levels are all useful signals alongside weight.

Second, calorie compensation. Semaglutide works partly by reducing appetite, but at a low starter dose the effect is subtle. Some people unconsciously replace smaller meal portions with more calorie-dense snacks, or drink more alcohol or juice. These aren't character flaws; they're patterns worth noticing. The NHS recommends pairing treatment with a reduced-calorie diet and increased physical activity, not because the medicine doesn't work without them, but because they amplify the results substantially. The NHS semaglutide medicines page explains this clearly.

Third, individual variation in drug response. Some people are slower metabolisers and find appetite changes more pronounced at higher doses. If you're only at the starter dose, you haven't yet reached the part of treatment most relevant to your biology.

What about 4 weeks on Wegovy specifically, is the injection version different?

The active ingredient in Wegovy injections is semaglutide 2.4mg at maintenance, and the mechanism is identical whether you're asking about four weeks on Wegovy or four weeks on semaglutide more broadly. The same titration logic applies: the first month is about tolerance, not transformation. If anything, the injectable form tends to produce more consistent blood levels than oral versions because absorption isn't affected by food timing or stomach conditions, but that advantage only becomes meaningful at doses above the starter level.

If you've been tracking your journey and want context on what to expect a little further along, our pages on the first two weeks and week six cover the progression in more detail. Some people also find that progress picks up noticeably once they move past the initial plateau, and if you're wondering whether your experience at the three-week point with no weight loss is typical, that page walks through what's usually happening at that stage. The five-week mark is often where things start to shift.

One practical note: Wegovy pens are prescription-only medicines, and your dose is set by a clinician for good reason. Please don't adjust your schedule based on what you read online. Your prescriber is the right person to discuss whether your titration is on track. If you're exploring what the full treatment landscape looks like, our Wegovy overview page covers eligibility, the dose schedule and what the NHS pathway looks like versus the private route.

When should you actually be concerned?

No weight loss at four weeks is not a red flag. Persistent absence of any response (no appetite change, no shift in weight, nothing after reaching and staying on the maintenance dose for several months) is worth raising with your prescriber. NICE guidance notes that if less than 5% weight loss has occurred after six months on the highest tolerated dose, continuing treatment should be reviewed. That's a six-month window, not a four-week one.

Separately, if you're experiencing side effects that feel severe or unusual (particularly persistent, intense stomach pain that radiates to your back) seek medical help promptly. The MHRA has highlighted acute pancreatitis as a rare but serious risk with GLP-1 medicines, and it warrants urgent attention rather than waiting for your next check-in. You can report any suspected side effects via the MHRA Yellow Card scheme.

For most people at the four-week point, the right move is patience and an honest look at diet and activity patterns while the dose builds. If you're on a private prescription and have questions about your progress, speaking with a clinician who can review your full picture is always the most useful next step. You can speak to our prescribers if you'd like that clinical perspective.